1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Cancers Immunotherapy Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Monoclonal Antibodies 1.2.3 Check Point Inhibitors 1.2.4 Interferons 1.2.5 Interleukins 1.3 Market by Application 1.3.1 Global Cancers Immunotherapy Drugs Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Lung Cancer 1.3.3 Liver Cancer 1.3.4 Colorectal Cancer 1.3.5 Pancreatic Cancer 1.3.6 Breast Cancer 1.3.7 Other Cancers 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Cancers Immunotherapy Drugs Market Perspective (2017-2028) 2.2 Cancers Immunotherapy Drugs Growth Trends by Region 2.2.1 Cancers Immunotherapy Drugs Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Cancers Immunotherapy Drugs Historic Market Size by Region (2017-2022) 2.2.3 Cancers Immunotherapy Drugs Forecasted Market Size by Region (2023-2028) 2.3 Cancers Immunotherapy Drugs Market Dynamics 2.3.1 Cancers Immunotherapy Drugs Industry Trends 2.3.2 Cancers Immunotherapy Drugs Market Drivers 2.3.3 Cancers Immunotherapy Drugs Market Challenges 2.3.4 Cancers Immunotherapy Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Cancers Immunotherapy Drugs Players by Revenue 3.1.1 Global Top Cancers Immunotherapy Drugs Players by Revenue (2017-2022) 3.1.2 Global Cancers Immunotherapy Drugs Revenue Market Share by Players (2017-2022) 3.2 Global Cancers Immunotherapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Cancers Immunotherapy Drugs Revenue 3.4 Global Cancers Immunotherapy Drugs Market Concentration Ratio 3.4.1 Global Cancers Immunotherapy Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Cancers Immunotherapy Drugs Revenue in 2021 3.5 Cancers Immunotherapy Drugs Key Players Head office and Area Served 3.6 Key Players Cancers Immunotherapy Drugs Product Solution and Service 3.7 Date of Enter into Cancers Immunotherapy Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Cancers Immunotherapy Drugs Breakdown Data by Type 4.1 Global Cancers Immunotherapy Drugs Historic Market Size by Type (2017-2022) 4.2 Global Cancers Immunotherapy Drugs Forecasted Market Size by Type (2023-2028) 5 Cancers Immunotherapy Drugs Breakdown Data by Application 5.1 Global Cancers Immunotherapy Drugs Historic Market Size by Application (2017-2022) 5.2 Global Cancers Immunotherapy Drugs Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Cancers Immunotherapy Drugs Market Size (2017-2028) 6.2 North America Cancers Immunotherapy Drugs Market Size by Country (2017-2022) 6.3 North America Cancers Immunotherapy Drugs Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Cancers Immunotherapy Drugs Market Size (2017-2028) 7.2 Europe Cancers Immunotherapy Drugs Market Size by Country (2017-2022) 7.3 Europe Cancers Immunotherapy Drugs Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Cancers Immunotherapy Drugs Market Size (2017-2028) 8.2 Asia-Pacific Cancers Immunotherapy Drugs Market Size by Country (2017-2022) 8.3 Asia-Pacific Cancers Immunotherapy Drugs Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Cancers Immunotherapy Drugs Market Size (2017-2028) 9.2 Latin America Cancers Immunotherapy Drugs Market Size by Country (2017-2022) 9.3 Latin America Cancers Immunotherapy Drugs Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Cancers Immunotherapy Drugs Market Size (2017-2028) 10.2 Middle East & Africa Cancers Immunotherapy Drugs Market Size by Country (2017-2022) 10.3 Middle East & Africa Cancers Immunotherapy Drugs Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Detail 11.1.2 Roche Business Overview 11.1.3 Roche Cancers Immunotherapy Drugs Introduction 11.1.4 Roche Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.1.5 Roche Recent Development 11.2 Pfizer 11.2.1 Pfizer Company Detail 11.2.2 Pfizer Business Overview 11.2.3 Pfizer Cancers Immunotherapy Drugs Introduction 11.2.4 Pfizer Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.2.5 Pfizer Recent Development 11.3 Merck 11.3.1 Merck Company Detail 11.3.2 Merck Business Overview 11.3.3 Merck Cancers Immunotherapy Drugs Introduction 11.3.4 Merck Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.3.5 Merck Recent Development 11.4 Novartis 11.4.1 Novartis Company Detail 11.4.2 Novartis Business Overview 11.4.3 Novartis Cancers Immunotherapy Drugs Introduction 11.4.4 Novartis Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.4.5 Novartis Recent Development 11.5 Johnson & Johnson 11.5.1 Johnson & Johnson Company Detail 11.5.2 Johnson & Johnson Business Overview 11.5.3 Johnson & Johnson Cancers Immunotherapy Drugs Introduction 11.5.4 Johnson & Johnson Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.5.5 Johnson & Johnson Recent Development 11.6 Sanofi 11.6.1 Sanofi Company Detail 11.6.2 Sanofi Business Overview 11.6.3 Sanofi Cancers Immunotherapy Drugs Introduction 11.6.4 Sanofi Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.6.5 Sanofi Recent Development 11.7 GlaxoSmithKline 11.7.1 GlaxoSmithKline Company Detail 11.7.2 GlaxoSmithKline Business Overview 11.7.3 GlaxoSmithKline Cancers Immunotherapy Drugs Introduction 11.7.4 GlaxoSmithKline Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.7.5 GlaxoSmithKline Recent Development 11.8 Amgen 11.8.1 Amgen Company Detail 11.8.2 Amgen Business Overview 11.8.3 Amgen Cancers Immunotherapy Drugs Introduction 11.8.4 Amgen Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.8.5 Amgen Recent Development 11.9 AbbVie 11.9.1 AbbVie Company Detail 11.9.2 AbbVie Business Overview 11.9.3 AbbVie Cancers Immunotherapy Drugs Introduction 11.9.4 AbbVie Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.9.5 AbbVie Recent Development 11.10 Boehringer Ingelheim 11.10.1 Boehringer Ingelheim Company Detail 11.10.2 Boehringer Ingelheim Business Overview 11.10.3 Boehringer Ingelheim Cancers Immunotherapy Drugs Introduction 11.10.4 Boehringer Ingelheim Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.10.5 Boehringer Ingelheim Recent Development 11.11 AstraZeneca 11.11.1 AstraZeneca Company Detail 11.11.2 AstraZeneca Business Overview 11.11.3 AstraZeneca Cancers Immunotherapy Drugs Introduction 11.11.4 AstraZeneca Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.11.5 AstraZeneca Recent Development 11.12 Immatics Biotechnologies 11.12.1 Immatics Biotechnologies Company Detail 11.12.2 Immatics Biotechnologies Business Overview 11.12.3 Immatics Biotechnologies Cancers Immunotherapy Drugs Introduction 11.12.4 Immatics Biotechnologies Revenue in Cancers Immunotherapy Drugs Business (2017-2022) 11.12.5 Immatics Biotechnologies Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Cancers Immunotherapy Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Monoclonal Antibodies Table 3. Key Players of Check Point Inhibitors Table 4. Key Players of Interferons Table 5. Key Players of Interleukins Table 6. Global Cancers Immunotherapy Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Cancers Immunotherapy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Cancers Immunotherapy Drugs Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Cancers Immunotherapy Drugs Market Share by Region (2017-2022) Table 10. Global Cancers Immunotherapy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Cancers Immunotherapy Drugs Market Share by Region (2023-2028) Table 12. Cancers Immunotherapy Drugs Market Trends Table 13. Cancers Immunotherapy Drugs Market Drivers Table 14. Cancers Immunotherapy Drugs Market Challenges Table 15. Cancers Immunotherapy Drugs Market Restraints Table 16. Global Cancers Immunotherapy Drugs Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Cancers Immunotherapy Drugs Market Share by Players (2017-2022) Table 18. Global Top Cancers Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancers Immunotherapy Drugs as of 2021) Table 19. Ranking of Global Top Cancers Immunotherapy Drugs Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Cancers Immunotherapy Drugs Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Cancers Immunotherapy Drugs Product Solution and Service Table 23. Date of Enter into Cancers Immunotherapy Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Cancers Immunotherapy Drugs Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Cancers Immunotherapy Drugs Revenue Market Share by Type (2017-2022) Table 27. Global Cancers Immunotherapy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Cancers Immunotherapy Drugs Revenue Market Share by Type (2023-2028) Table 29. Global Cancers Immunotherapy Drugs Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Cancers Immunotherapy Drugs Revenue Market Share by Application (2017-2022) Table 31. Global Cancers Immunotherapy Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Cancers Immunotherapy Drugs Revenue Market Share by Application (2023-2028) Table 33. North America Cancers Immunotherapy Drugs Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Cancers Immunotherapy Drugs Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Cancers Immunotherapy Drugs Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Cancers Immunotherapy Drugs Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Cancers Immunotherapy Drugs Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Cancers Immunotherapy Drugs Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Cancers Immunotherapy Drugs Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Cancers Immunotherapy Drugs Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Cancers Immunotherapy Drugs Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Cancers Immunotherapy Drugs Market Size by Country (2023-2028) & (US$ Million) Table 43. Roche Company Detail Table 44. Roche Business Overview Table 45. Roche Cancers Immunotherapy Drugs Product Table 46. Roche Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 47. Roche Recent Development Table 48. Pfizer Company Detail Table 49. Pfizer Business Overview Table 50. Pfizer Cancers Immunotherapy Drugs Product Table 51. Pfizer Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 52. Pfizer Recent Development Table 53. Merck Company Detail Table 54. Merck Business Overview Table 55. Merck Cancers Immunotherapy Drugs Product Table 56. Merck Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 57. Merck Recent Development Table 58. Novartis Company Detail Table 59. Novartis Business Overview Table 60. Novartis Cancers Immunotherapy Drugs Product Table 61. Novartis Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 62. Novartis Recent Development Table 63. Johnson & Johnson Company Detail Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Cancers Immunotherapy Drugs Product Table 66. Johnson & Johnson Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 67. Johnson & Johnson Recent Development Table 68. Sanofi Company Detail Table 69. Sanofi Business Overview Table 70. Sanofi Cancers Immunotherapy Drugs Product Table 71. Sanofi Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 72. Sanofi Recent Development Table 73. GlaxoSmithKline Company Detail Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline Cancers Immunotherapy Drugs Product Table 76. GlaxoSmithKline Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 77. GlaxoSmithKline Recent Development Table 78. Amgen Company Detail Table 79. Amgen Business Overview Table 80. Amgen Cancers Immunotherapy Drugs Product Table 81. Amgen Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 82. Amgen Recent Development Table 83. AbbVie Company Detail Table 84. AbbVie Business Overview Table 85. AbbVie Cancers Immunotherapy Drugs Product Table 86. AbbVie Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 87. AbbVie Recent Development Table 88. Boehringer Ingelheim Company Detail Table 89. Boehringer Ingelheim Business Overview Table 90. Boehringer Ingelheim Cancers Immunotherapy Drugs Product Table 91. Boehringer Ingelheim Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 92. Boehringer Ingelheim Recent Development Table 93. AstraZeneca Company Detail Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Cancers Immunotherapy DrugsProduct Table 96. AstraZeneca Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 97. AstraZeneca Recent Development Table 98. Immatics Biotechnologies Company Detail Table 99. Immatics Biotechnologies Business Overview Table 100. Immatics Biotechnologies Cancers Immunotherapy DrugsProduct Table 101. Immatics Biotechnologies Revenue in Cancers Immunotherapy Drugs Business (2017-2022) & (US$ Million) Table 102. Immatics Biotechnologies Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Cancers Immunotherapy Drugs Market Share by Type: 2021 VS 2028 Figure 2. Monoclonal Antibodies Features Figure 3. Check Point Inhibitors Features Figure 4. Interferons Features Figure 5. Interleukins Features Figure 6. Global Cancers Immunotherapy Drugs Market Share by Application in 2021 & 2028 Figure 7. Lung Cancer Case Studies Figure 8. Liver Cancer Case Studies Figure 9. Colorectal Cancer Case Studies Figure 10. Pancreatic Cancer Case Studies Figure 11. Breast Cancer Case Studies Figure 12. Other Cancers Case Studies Figure 13. Cancers Immunotherapy Drugs Report Years Considered Figure 14. Global Cancers Immunotherapy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 15. Global Cancers Immunotherapy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 16. Global Cancers Immunotherapy Drugs Market Share by Region: 2021 VS 2028 Figure 17. Global Cancers Immunotherapy Drugs Market Share by Players in 2021 Figure 18. Global Top Cancers Immunotherapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancers Immunotherapy Drugs as of 2021) Figure 19. The Top 10 and 5 Players Market Share by Cancers Immunotherapy Drugs Revenue in 2021 Figure 20. North America Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. North America Cancers Immunotherapy Drugs Market Share by Country (2017-2028) Figure 22. United States Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Canada Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Europe Cancers Immunotherapy Drugs Market Share by Country (2017-2028) Figure 26. Germany Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. France Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. U.K. Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Italy Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Russia Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Nordic Countries Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Cancers Immunotherapy Drugs Market Share by Region (2017-2028) Figure 34. China Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Japan Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. South Korea Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Southeast Asia Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. India Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Australia Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Latin America Cancers Immunotherapy Drugs Market Share by Country (2017-2028) Figure 42. Mexico Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Brazil Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Middle East & Africa Cancers Immunotherapy Drugs Market Share by Country (2017-2028) Figure 46. Turkey Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. Saudi Arabia Cancers Immunotherapy Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Roche Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 49. Pfizer Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 50. Merck Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 51. Novartis Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 52. Johnson & Johnson Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 53. Sanofi Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 54. GlaxoSmithKline Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 55. Amgen Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 56. AbbVie Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 57. Boehringer Ingelheim Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 58. AstraZeneca Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 59. Immatics Biotechnologies Revenue Growth Rate in Cancers Immunotherapy Drugs Business (2017-2022) Figure 60. Bottom-up and Top-down Approaches for This Report Figure 61. Data Triangulation Figure 62. Key Executives Interviewed

Roche Pfizer Merck Novartis Johnson & Johnson Sanofi GlaxoSmithKline Amgen AbbVie Boehringer Ingelheim AstraZeneca Immatics Biotechnologies